Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy

Immunosuppressive therapy increases the risk of pneumococcal disease. This risk can be mitigated by pneumococcal vaccination. The objective of this study was to investigate the immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13), followed by the 23-valent pneumococcal polysacchari...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Hannah M. Garcia Garrido, Albert Vollaard, Geert R. D’Haens, Phyllis I. Spuls, Frederike J. Bemelman, Michael W. Tanck, Godelieve J. de Bree, Bob Meek, Martin P. Grobusch, Abraham Goorhuis
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	MDPI AG 2022-05-01
סדרה:	Vaccines
נושאים:	pneumococcal vaccination immunocompromised host transplant recipient autoimmune disease vaccine immunogenicity
גישה מקוונת:	https://www.mdpi.com/2076-393X/10/5/795
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!